KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Japan flag Japan · Delayed Price · Currency is JPY
1,505.00
+35.00 (2.38%)
May 30, 2025, 3:30 PM JST
-11.63%
Market Cap 86.46B
Revenue (ttm) 130.09B
Net Income (ttm) 9.09B
Shares Out 57.45M
EPS (ttm) 158.16
PE Ratio 9.52
Forward PE 22.40
Dividend 57.00 (3.79%)
Ex-Dividend Date Mar 28, 2025
Volume 128,500
Average Volume 110,770
Open 1,466.00
Previous Close 1,470.00
Day's Range 1,459.00 - 1,505.00
52-Week Range 1,331.00 - 1,751.00
Beta -0.07
RSI 59.69
Earnings Date May 12, 2025

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis th... [Read more]

Sector Healthcare
Founded 1923
Employees 2,042
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4569
Full Company Profile

Financial Performance

In 2024, KYORIN Pharmaceutical's revenue was 130.09 billion, an increase of 8.83% compared to the previous year's 119.53 billion. Earnings were 9.09 billion, an increase of 70.73%.

Financial Statements

News

There is no news available yet.